Vista Exclusive Content
Australian Competition and Consumer Commission Pushes Forward GSK-Pfizer Consumer Healthcare Business
The GlaxoSmithKline’ deal seeking to purchase & combine Pfizer’s consumer healthcare business with their own has recently received approval from Australia’s antitrust regulator recently called the Australian Competition and Consumer Commission (ACCC.) It was reported that the ACCC anticipates that the new partnership will face
Pfizer’s Drug For Treating Fatal Heart Disease Gains FDA Approval
Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Pfizer Inc.’s oral drug tafamidis effective in treating “transthyretin amyloid cardiomyopathy”, a rare and fatal heart disease recently gained approval from the U.S
“Earnings are Back” – Vista Partners Daily Market Recap 4/30/2019
Earnings once again took the spotlight during Tuesday’s session, while stocks ended the session mixed. The S&P 500 started in the red and then climbed to break even. It ended the day up 0.10% (2.80 points). The Nasdaq, on the other hand, was never able
Company News Around The Web
19 May 2019 | 1:00 pm
Better Buy: Eli Lilly vs. Pfizer
Which stock wins in a matchup between these two big drugmake...
18 May 2019 | 10:30 am
Where Will Pfizer Be in 5 Years?
The last five years were good for Pfizer shareholders. Here&...
17 May 2019 | 12:35 pm
Pharma Stock Roundup: FDA Okays Line Extensions...
FDA grants approval for line extensions of Lilly (LLY), Pfiz...
17 May 2019 | 12:24 pm
Dow 30 Stock Roundup: Walmart, Cisco Earnings...
The index enjoyed a strong week of gains after the after U.S...
16 May 2019 | 1:40 pm
Pfizer Gains After Being Named 'Top Pick'...
posted gains on Thursday after the drugmaker was named a "to...
16 May 2019 | 12:20 pm
Pfizer's Eczema Candidate Meets All Goals in...
Pfizer's (PFE) investigational eczema treatment abrocit...
|Day Low - High||-|
|Year Low - High||-|